Cardiovascular-kidney-metabolic syndrome in the tumor host macroenvironment: organ crosstalk, treatment trajectories, and net clinical benefit
4 affiliations
- 1Graduate School, Guangxi University of Chinese Medicine, Nanning, Guangxi, China
- 2Center for General Practice Medicine, General Practice and Health Management Center, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, Zhejiang, China
- 3The Second Affiliated Hospital of Guangxi University of Chinese Medicine, Nanning, Guangxi Zhuang Autonomous Region, China
- 4The Department of Pharmacy, The Second People’s Hospital of Longgang District, Shenzhen, China
Abstract
Cardiovascular-kidney-metabolic (CKM) syndrome links metabolic dysfunction, chronic kidney disease, and cardiovascular disease, yet oncology commonly treats these conditions as separate comorbidities. This review examines CKM as a measurable component of the tumor host macroenvironment that may influence treatment tolerance and competing mortality. We integrate adipose, cardiorenal, and immune-metabolic pathways; clonal hematopoiesis is considered as a candidate link between inflammation, vascular injury, and treatment exposure, rather than a CKM staging criterion. Cancer and its treatment can also alter CKM status through organ injury and catabolism. Population studies associate higher CKM stages with cancer incidence and adverse host outcomes, but evidence for cancer-specific mortality and treatment efficacy remains inconsistent or limited. The central question is therefore whether CKM captures biologically meaningful host variation that changes tumor natural history, treatment tolerance, or both. Our oncology-adapted phenotyping framework retains the original American Heart Association CKM stages and adds organ reserve and activity, tumor and treatment context, and longitudinal change. It applies to both patients with active cancer and survivors, without introducing a new stage or stage-specific treatment recommendation. We outline assessment from pretreatment to survivorship and distinguish established cardiorenal indications from exploratory anticancer effects of CKM therapies. Net clinical benefit requires joint assessment of tumor control, treatment delivery, cardiorenal events, function, and patient priorities. Prospective validation is needed before the added phenotypes can guide cancer-treatment selection.
Related
- Choosing depression treatment in type 2 diabetes: integrating psychiatric efficacy, metabolic effects, and cardiovascular risk. A narrative review
- β3-Integrin controls pericyte metabolic states and shapes tumour-stromal metabolic crosstalk in breast cancer
- Solute carrier transporters as metabolic gatekeepers in tumor-microenvironment crosstalk
- Bidirectional metabolic-vascular feedback loops in heart failure: From myocardial energetics to multisystem cardiometabolic crosstalk
- Cumulative exposure and trajectories of cardiovascular health in relation to hepatic steatosis risk in children: a 6-year longitudinal study
BibTeX
@article{jia2026cardiovascularkidneymetabolic,
title = {{Cardiovascular-kidney-metabolic syndrome in the tumor host macroenvironment: organ crosstalk, treatment trajectories, and net clinical benefit}},
author = {Ming-Jie Jia and Jie Zhou and Ying-Lu Ma and Feng Jiang and Fei-Qing Liang},
journal = {Frontiers in Oncology},
year = {2026},
month = nov,
doi = {10.3389/fonc.2026.1982021},
url = {https://doi.org/10.3389/fonc.2026.1982021},
note = {CC BY},
}
RIS
TY - JOUR
TI - Cardiovascular-kidney-metabolic syndrome in the tumor host macroenvironment: organ crosstalk, treatment trajectories, and net clinical benefit
AU - Ming-Jie Jia
AU - Jie Zhou
AU - Ying-Lu Ma
AU - Feng Jiang
AU - Fei-Qing Liang
PY - 2026
DA - 2026/11/09
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1982021
UR - https://doi.org/10.3389/fonc.2026.1982021
AB - Cardiovascular-kidney-metabolic (CKM) syndrome links metabolic dysfunction, chronic kidney disease, and cardiovascular disease, yet oncology commonly treats these conditions as separate comorbidities. This review examines CKM as a measurable component of the tumor host macroenvironment that may influence treatment tolerance and competing mortality. We integrate adipose, cardiorenal, and immune-metabolic pathways; clonal hematopoiesis is considered as a candidate link between inflammation, vascular injury, and treatment exposure, rather than a CKM staging criterion. Cancer and its treatment can also alter CKM status through organ injury and catabolism. Population studies associate higher CKM stages with cancer incidence and adverse host outcomes, but evidence for cancer-specific mortality and treatment efficacy remains inconsistent or limited. The central question is therefore whether CKM captures biologically meaningful host variation that changes tumor natural history, treatment tolerance, or both. Our oncology-adapted phenotyping framework retains the original American Heart Association CKM stages and adds organ reserve and activity, tumor and treatment context, and longitudinal change. It applies to both patients with active cancer and survivors, without introducing a new stage or stage-specific treatment recommendation. We outline assessment from pretreatment to survivorship and distinguish established cardiorenal indications from exploratory anticancer effects of CKM therapies. Net clinical benefit requires joint assessment of tumor control, treatment delivery, cardiorenal events, function, and patient priorities. Prospective validation is needed before the added phenotypes can guide cancer-treatment selection.
SN - 2234-943X
ER -